First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

BACKGROUND: IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8(+ )T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Brignone, Chrystelle, Gutierrez, Maya, Mefti, Fawzia, Brain, Etienne, Jarcau, Rosana, Cvitkovic, Frédérique, Bousetta, Nabil, Medioni, Jacques, Gligorov, Joseph, Grygar, Caroline, Marcu, Manon, Triebel, Frédéric
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2010
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2920252/
https://ncbi.nlm.nih.gov/pubmed/20653948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-71
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia